Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 7, 2019 (7 years ago)

Clotrimazole and Betamethasone Dipropionate Cream USP

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Temperature Abuse: Complaints received of liquidy texture.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%, 15 gram tubes, Rx only, Manufactured by: Glenmark Pharmaceuticals Ltd. Village: Kishanpura, Baddi Nalagarth Road, District: Solan, Himachal Pradesh-173205, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 68462-298-17

Affected NDC 68462-0298-17

Compare with the code on your package — it is the most precise check available.

Drug: Betamethasone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Clotrimazole and Betamethasone Dipropionate
NDC 68462-0298
CLOTRIMAZOLE 10 mg/g; BETAMETHASONE DIPROPIONATE .5 mg/g Cream
Topical
Glenmark Pharmaceuticals Inc. USA Rx
Recalling firm
Glenmark Pharmaceuticals Inc., USA
NDC code
68462-298-17
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1743-2019 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Betamethasone recalls

See all
Class II · Moderate risk

Betamethasone Dipropionate Ointment USP

CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

Ongoing Stability / shelf life McKesson Corporation dba McKesson Drug Company NDC 63739-996-65 D-0850-2022
Class II · Moderate risk

Celestone Soluspan

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0085-4320-01 D-1089-2022

Other recalls by Glenmark Pharmaceuticals Inc., USA

All 2019 recalls
Class II · Moderate risk

Azelaic Acid Gel

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-626-52 D-0731-2026
Class II · Moderate risk

Alyacen 7/7/7

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk

Ondansetron Orally Disintegrating Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-157-13 D-0246-2026